Abstract
Adverse drug–alcohol interactions represent a major problem in today’s society because of the increasing use of prescription medication in the aging population and the recreational use and abuse of alcoholic beverages throughout adult life. Heavy drinking and drunkenness are major public health problems and ethanol is the drug most frequently encountered in poisoning deaths either alone or together with other substances. Drugs and alcohol can interact in a number of ways, such as by competition for binding sites on hepatic enzymes, which opens the possibility for a metabolic interaction. This is often reflected in a change in the blood or plasma concentration–time curve of alcohol and/or drug and a more rapid or slower rate of elimination from the body (pharmacokinetic interaction). The combined influence of alcohol and other drugs might occur at certain receptor sites or ion channels in the central nervous system and in this way modify behavioral response to drug treatment (pharmacodynamic interaction). This review is concerned with the biological background and the mechanism underlying pharmacokinetic and pharmacodynamic interaction between ethanol and other drugs. Examples are given of ethanol–drug interactions involving common medications (e.g., acetaminophen, benzodiazepines, and other sedatives) as well as drugs of abuse, such as cocaine and GHB.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Conti A and Bickel MH. History of drug metabolism Discoveries of the major pathways of the 19th century. Drug Metab Rev 6:1–50 (1977).
Bachmann C and Bickel MH. History of drug metabolism: the first half of the 20th century. Drug Metab Rev 16:185–253 (1985).
Williams RT. Detoxication mechanisms. London, Chapman & Hall Ltd, (1959).
Anstie FE. On the physiological and therapeutic action of alcohol. Lancet 343–5 (1865).
Anstie FE. Final experiments on the elimination of alcohol from the body. The Practitioner 13:15–28 (1874).
Neubauer, O. Uber Glukuronsaure paarung bei Stoffen der Fettreihe. Arch Exp Pathol Pharmacol, 46, 133 (1901).
Launiainen T, Vuori E and Ojanpera I. Prevalence of adverse drug combinations in a large post-mortem toxicology database. Int J Legal Med 123:109–115 (2009).
Carson HJ. Classes of drugs and their prevalence in multiple drug intoxication in suicides and accidents. Leg Med 10:92–95 (2008).
Koski A, Ojanperä I and Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Exp Toxicol 22:281–287 (2003).
Koski A, Vuori E and Ojanperä I. Relation of postmortem blood alcohol and drug concentrations in fatal poisonings involving amitriptyline, propoxyphene and promazine. Hum Exp Toxicol 24:389–396 (2005).
Edwards IR and Aronson JK. Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255–1259 (2000).
Phillips DP, Barker GE and Eguchi MM. A steep increase in domestic fatal medication errors with use of alcohol and/or street drugs. Arch Intern Med 168:1561–1566 (2008).
Hickman M, Carrivick S, Paterson S, Hunt N, Zador D, Cusick L and Henry J. London audit of drug-related overdose deaths: characteristics and typology, and implications for prevention and monitoring. Addiction 102:317–323 (2007).
Roche AM, Watt K, McClure R, Purdi DM and Green D. Injury and alcohol: a hospital emergency department study. Drug Alc Rev 20:155–166 (2001).
Rivara FP, Mueller BA, Somes G, Menoza CT, Rushforth NB and Kellermann AL. Alcohol and illicit drug abuse and the risk of violent death in the home. JAMA 278:569–575 (1997).
Gibbons B. Alcohol – the legal drug. Nat Geographic 181:3–35 (1992).
Fell JC, Fisher DA, Voas RB, Blackman K and Tippetts AS. The impact of underage drinking laws on alcohol-related fatal crashes of young drivers. Alcohol Clin Exp Res 33:1–12 (2009).
Pirmohamed, M, James S, Meakin S and Green C, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15–19 (2004).
Juntti-Patinen L, Kuitunen T, Pere P and Neuvonen PJ. Drug-related visits to a district hospital emergency room. Basic Clin Pharmacol Toxicol 98:212–217 (2006).
Hall AJ, Logan JE, Toblin RL and Kaplan JA, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 300:2613–2620 (2008).
Movig KL, Mathijssen MP, Nagel PH, and van Egmond T et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 36:631–636 (2004).
Jones AW, Kugelberg FC, Holmgren A and Ahlner J. Five-year update on the occurrence of alcohol and other drugs in blood samples from drivers killed in road-traffic crashes in Sweden. Forensic Sci Int 186:56–62 (2009).
Gonzalez-Wilhelm L. Prevalence of alcohol and illicit drugs in blood specimens from drivers involved in traffic law offences. Systematic review of cross-sectional studies. Traffic Inj Prev 8:189–98 (2007).
Ropero-Miller JD and Goldberger BA. Recreational drugs – current trends in the 90s. Clin Lab Med 18:727–746 (1998).
Britt GC and McCance-Katz EF. A brief overview of the clinical pharmacology of club drugs. Substance Use & Misuse 40:1189–1201 (2005).
Ricaurte GA and McCann UD. Recognition and management of complications of new recreational drug use. Lancet 365:2137–45 (2005).
Jones AW and Holmgren A. Age and gender differences in blood-alcohol concentration in apprehended drivers in relation to the amounts of alcohol consumed. Forensic Sci Int 188:40–45 (2009).
Griffin JP. Drug interactions occurring during absorption from the gastrointestinal tract. Pharmacol Ther 15:79–88 (1981).
Baillie TA. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 21:129–37 (2008).
Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H and Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interactions in the liver. Pharmacol Rev 50:335–492 (1998).
Hines RN. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250–67 (2008).
Offerhaus L. Drug interactions at excretory mechanisms. Pharmacol Ther 15:69–78 (1981).
Gardiner SJ and Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521–90 (2006).
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–21 (2005).
Eichelbaum M, Ingelman-Sundberg M and Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119–37 (2006).
Roberts DM and Buckley NA. Pharmacokinetic considerations in clinical toxicology: clinical applications. Clin Pharmacokinet 46:897–939 (2007).
Navarro VJ and Senior JR. Drug-related hepatotoxicity. N Engl J Med 354:731–9 (2006).
Senior JR. Monitoring for hepatoxicity: What is the predictive value of liver function tests. Clin Pharmacol Therap 85:331–334 (2009).
Schlatter C, Egger SS, Tchambaz L and Krähenbühl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 32:561–78 (2009).
Mallet L, Spinewine A and Huang A. The challenge of managing drug interactions in elderly people. Lancet 370:185–191 (2007).
Herrlinger C and Klotz U. Drug metabolism and drug interactions in the elderly. Best Pract Res Clin Gastroenterol 15:897–918 (2001).
Shi S, Morike K and Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64:183–99 (2008).
Klotz U. The elderly-a challenge for appropriate drug treatment. Eur J Clin Pharmacol 64:225–226 (2008).
Koob GF. A role of GABA in alcohol dependence. Adv Pharmacol 54:205–229 (2006).
Cruz MT, Bajo M, Schweitzer P and Roberto M. Shared mechanisms of alcohol and other drugs. Alc Res Health 31:137–147 (2009).
Clapp P, Bhave SV and Hoffman PL. How adaptation of the brain to alcohol leads to dependence. Alc Res Health 31:310–339 (2009).
Krystal JH, Petrakis IL and Mason G. et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment and vulnerability. Pharmac Therap 99:79–94 (2003).
Spanagel R and Heilig M. Addiction and its brain science. Addiction 100:1813–22 (2005).
Kalant H, LeBlanc SE and Gibbins RJ. Tolerance to and dependence on some non-opiate psychotropic drugs. Pharmacol Rev 23:135–191 (1971).
Chesher G and Greeley J. Tolerance to the effects of alcohol. Alc Drugs Driving 8:93–106 (1992).
Brick J and Erickson CK. Intoxication is not always visible: An unrecognized prevention challenge. Alcohol Clin Exp Res 33:1–19 (2009).
Coleman MD. Human drug metabolism – an introduction. John Wiley & Sons, Chichester, (2005).
Shenton JM, Chen J and Uetrecht JP. Animal models of idiosyncratic drug reactions. Chem Biol Interact 150:53–70 (2004).
Li AP. Preclinical evaluation of drug-drug interactions using human in vitro experimental systems. IDrugs 1:311–314 (1998).
Li AP. Human-based in vitro experimental systems for the evaluation of human drug safety. Curr Drug Saf 2:193–9 (2007).
Forney RB and Hughes FW. Combined effects of alcohol and other drugs. Charles C. Thomas Publisher, Springfield (1968).
Pirola RC. Drug metabolism and alcohol. University Park Press, Baltimore (1978).
Milner G. Drugs and driving. S. Karger, Basel (1972).
Mattila MJ. Alcohol, drugs and driving. S Karger, Basel (1976).
Kuitunen T. Drug and ethanol effects on the clinical test for drunkenness: single doses of ethanol, hypnotic drugs and antidepressant drugs. Pharmacol Toxicol 75:91–98 (1994).
Mattila MJ, Kuitunen T and Plétan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 43:179–184 (1992).
Kuitunen T, Mattila MJ, Seppälä T, Aranko K and Mattila ME. Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests. Br J Clin Pharmacol 30:453–461 (1990).
Kuitunen T, Mattila MJ and Seppala T. Actions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol. Int Clin Psychopharmacol 5(2):115–130 (1990).
Mattila M, Mattila MJ, Vrijmoed-de Vries M and Kuitunen T. Actions and interactions of psychotropic drugs on human performance and mood: single doses of ORG 3770, amitriptyline, and diazepam. Pharmacol Toxicol 65:81–8 (1989).
Lane EA, Guthrie S and Linnoila M. Effects of ethanol on drug metabolite pharmacokinetics. Clin Pharmacokinet 10:228–247 (1985).
Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet 33:79–90 (1997).
Monroe ML and Doering PL. Effect of common over-the-counter medications on blood alcohol levels. Ann. Pharmacother 35:918–924 (2001).
Weathermon R and Crabb DW. Alcohol and medication interactions. Alc Res Health 23:40–54 (1999).
Havier RG. The interaction of ethanol with drugs. Forensic Sci Rev 3:41–56 (1991).
Starmer GA and Bird KD. Investigating drug-alcohol interactions. Br J Clin Pharmacol 18:27S-35S (1984).
Kelly TH, Foltin RW, Emurian CS and Fischman MW. Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol and diazepam. J Anal Toxicol 17:264–272 (1993).
Irving A and Jones W. Methods for testing impairment of driving due to drugs. Eur J Clin Pharmacol 43:61–66 (1992).
Kelly M, Myrsten AL, Neri A and Rydberg U. Effects and after-effects of alcohol on psychological and physiological functions in man. Blutalkohol 7:422–436 (1970).
Parker RA. Studies should be controlled, randomized and blinded. Clin Pharmacol therap 85:461–463 (2009).
Boehmer J and Yong P. How well does blinding work in randomized controlled trials?: a counterpoint. Clin Pharmacol Ther 85:463–465 (2009).
Hróbjartsson A and Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256:91–100 (2004).
Shapiro AK and Shapiro E. The powerful placebo. The Johns Hopkins University Press, Baltimore (1997).
Hrobjartsson A and Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 344:1594–1602 (2001).
Moskowitz H and Fiorentino D. A review of the scientific literature regarding the effects of alcohol on driving-related behavior at blood alcohol concentrations of 0.08 grams per deciliter and lower. US Department of Transportation, National Highway Traffic Safety Administration, Washington, (2000).
Kennedy RS, Turnage JJ, Wilkes RL and Dunlap WP. Effects of graded dosages of alcohol on nine computerized repeated-measures tests. Ergonomics 36:1195–1222 (1993).
Kunsman GW, Manno JE, Manno BR, Kunsman CM and Przekop MA. The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazapine. Br J Clin Pharmacol 34:289–301 (1992).
Holmgren A, Holmgren P, Kugelberg FC, Jones AW and Ahlner J. Predominance of illicit drugs and poly-drug use among drug-impaired drivers in Sweden. Traffic Inj Prev 8;361–367 (2007).
Jones AW. Driving under the influence of drugs in Sweden with zero-concentration limits in blood for controlled substances. Traffic Inj Prev 5; 317–322 (2005).
Farrell LJ and Logan BK. The effects of drugs on human performance and behavior. Forensic Sci Rev 14:1–151 (2002).
Mezey E. Ethanol metabolism and ethanol-drug interactions. Biochem Pharmacol 25:869–874 (1976).
Linnoila M, Mattila MJ and Kitchell BS. Drug interactions with alcohol. Drugs 18:299–311 (1979).
Lieber CS. Interaction of alcohol with other drugs and nutrients: Implications for the therapy of alcoholic liver disease. Drugs 40: Suppl 3, 23–44 (1990).
Hoyumpa AM and Schenker S. Major drug interactions: Effect of liver disease, alcohol, and malnutrition. Ann Rev Med 33:113–149 (1982).
Mattila MJ. Alcohol and drug interactions. Ann Med 22:363–369 (1990).
Kalant H. Pharmacokinetics of ethanol: absorption, distribution, and elimination, In: Begleiter H, Kissin B eds. The Pharmacology of alcohol and alcohol dependence. Oxford University Press, Oxford & New York, 1996, pp 15–58.
Ramchandani VA, Bosron WF and Li T-K. Research advances in ethanol metabolism. Pathol Biol 49:676–682 (2001).
Widmark EMP. Principles and applications of medicolegal alcohol determination. Biomedical Publications, Davis, CA (1981).
Holt S. Observations on the relation between alcohol absorption and the rate of gastric emptying. Can Med Assoc J 124:267–277 (1981).
Winek CL, Wahba WW and Dowdell JL. Determination of absorption time of ethanol in social drinkers. Forensic Sci Int 77:169–177 (1996).
Jones AW, Jönsson KÅ and Neri A. Peak blood-ethanol concentration and the time of its occurrence after rapid drinking on an empty stomach. J Forensic Sci 36:376–385 (1991).
Berggren SM and Goldberg L. The absorption of ethyl alcohol from the gastrointestinal tract as a diffusion process. Acta Physiol Scand 1:245–270 (1940).
Jones AW. Biochemical and physiological research on the disposition and fate of ethanol in the body. Chapter 3 in Medicolegal Aspects of Alcohol, 5th edition, J.C. Garriott. Ed. Lawyers & Judges Publishing Co., Inc., Tucson, 2008, pp 47–156.
Yelland LN, Burns JP, Sims DN, Salter AB and White JM. Inter- and intra-subject variability in ethanol pharmacokinetic parameters. Effects of testing interval and dose. Forensic Sci Int. 175:65–72 (2008).
Lotterle J, Husslein EM, Bolt J and Wirtz PM. Tageszeitliche Unterschiede der Alkoholresorption. Blutalkohol 26:369–375 (1989).
Schwartz JG, Salman UA, McMahan CA and Phillips WT. Gastric emptying of beer in Mexican-Americans compared with non-Hispanic whites. Metabolism 45:1174–1178 (1996).
Roine RP, Gentry RT, Lim RT, Baraona E and Lieber CS. Effect of concentration of ingested ethanol on blood alcohol levels. Alcohol Clin Exp Res 15:734–738 (1991).
Roine RP, Gentry RT, Lim RT, Heikkonen E, Salaspuro M and Lieber CS. Comparison of blood alcohol concentration after beer and whiskey. Alcohol Clin Exp Res 17:709–711 (1993).
Welling PG. Effects of food on drug absorption. Ann Rev Nutr 16:383–415 (1996).
Welling PG. Pharmacokinetics of alcohol following single low doses to fasted and non-fasted subjects. J Clin Pharmacol 17:199–206 (1977).
Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213–255 (1999).
Sedman, A.J., Wilkinson, P.K., Sakmar, D.J., Weidler, D.J., Wagner, J.G. Food effects on absorption and metabolism of alcohol. J Stud Alcohol 37:1197–1214 (1976).
Pikaar NA, Wedel M and Heemus RJJ. Influence of several factors on blood alcohol concentrations after drinking alcohol. Alc Alcohol 23:289–297 (1988).
Cortot A, Jobin G, Ducrot F, Aymes C, Giraudeaux V and Modigliani R. Gastric emptying and gastrointestinal absorption of alcohol ingested with a meal. Dig Dis Sci 31:343–348 (1986).
Schultz J, Weiner H and Wetscott J. Retardation of ethanol absorption by food in the stomach. J Stud Alcohol 41:861–870 (1980).
Jones AW and Jönsson KÅ. Food-induced lowering of blood-ethanol profiles and increased rate of elimination immediately after a meal. J Forensic Sci 39:1084–1093 (1994).
Jones AW, Jönsson K-Å and Kechagias S. Effect of high-fat, high-protein and high-carbohydrate meals on the pharmacokinetics of a small dose of alcohol. Br J Clin Pharmacol 44:521–526 (1997).
Ramchandani VA, Kwo PY and Li T-K. Effect of food and food composition on alcohol elimination rates in healthy men and women. J Clin Pharmacol 41:1345–1350 (2001).
McFarlane A, Pooley L, Welch IML, Rumsey RDE and Read NW. How does dietary lipid lower blood alcohol concentrations? Gut 27:15–18 (1986).
Rogers JO, Smith J, Starmer GA and Whitfield J. Differing effects of carbohydrate fat and protein on the rate of ethanol metabolism. Alc Alcohol 22:345–353 (1987).
O’Neill B, Williams AF and Dubowski KM. Variability in blood alcohol concentration: implications for estimating individual results. J Stud Alcohol 44:222–230 (1983).
Jones AW. Inter-individual variations in the disposition and metabolism of ethanol in healthy men. Alcohol 1:385–91 (1984).
Friel PN, Baer JS and Logan BK. Variability of ethanol absorption and breath concentrations during a large scale alcohol administration study. Alcohol Clin Exp Res 19:1055–1060 (1995).
Jones AW and Jönsson K-Å. Between subject and within subject variations in the pharmacokinetics of ethanol. Br J Clin Pharmacol 37:427–431 (1994).
Passananti GT, Wolff CA and Vesell ES. Reproducibility of individual rates of ethanol metabolism in fasting subjects. Clin Pharmacol Ther 47:389–396 (1990).
Jones AW and Neri A. (1985). Age-related changes in blood-alcohol parameters and subjective feelings of intoxication in healthy men. Alc Alcohol 20:45–52 (1985).
Hahn RG, Norberg Å and Jones AW. Over-shoot of ethanol in the blood after drinking on an empty stomach. Alc Alcohol 32:501–505 (1997).
Schvarcz E, Palmer M, Åman J and Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabet. Care 18:674–676 (1993).
Johnson RD, Horowitz M, Maddox AF, Wishart JM and Shearman DJC. Cigarette smoking and rate of gastric emptying - Effect on alcohol absorption. Br Med J 302:20–23 (1991).
Scott AM, Kellow JE, Shuter B, Nolan JM, Hoschl R and Jones MP. Effects of cigarette smoking on solid and liquid intragastric distribution and gastric emptying. Gastroenterology 104:410–416 (1993).
Klockhoff, H, Näslund I and Jones AW. Faster absorption of ethanol and higher peak concentration in women after gastric-bypass surgery. Br J Clin Pharmacol 54:587–591 (2002).
Bailey DN. Effect of coadministered drugs and ethanol on the binding of therapeutic drugs to human serum in-vitro. Ther Drug Monit 23:71–74 (2001).
Edelman IS and Leibman J. Anatomy of body water and electrolytes. Am. J. Med. 27:256–277 (1959).
Lucey MR, Hill E, Young JP, Demo-Dananberg L and Beresford TP. The influence of age and gender on blood ethanol concentrations in healthy humans. J. Stud. Alcohol 60:103–110 (1999).
Kwo PY, Ramchandani VA, O’Connor S, Amann D, Carr LG, Sandrasegaran K, Kopecky KK and Li T-K. Gender differences in alcohol metabolism: Relationship to liver volume and effect of adjusting for body mass. Gastroenterology 115:1552–1557 (1998).
Mumenthaler MS, Taylor JL and Yesavage JA. Ethanol pharmacokinetics in white women: Nonlinear model fitting versus zero-order elimination analysis. Alcohol. Clin. Exp. Res. 24:1353–1362 (2000).
Mumenthaler MS, O’Hara R, Taylor JL, Friedman L and Yesavage JA. Influence of menstrual cycle on flight simulator performance after alcohol ingestion. J. Stud. Alcohol 62:422–433 (2001).
Hobbes J, Boutagy J and Shenfield, GM. Interaction between ethanol and oral contraceptive steroids. Clin. Pharmacol. Therap. 38:157–163 (1987).
Marshall AW, Kingstone D, Boss M and Morgan MY. Ethanol elimination in males and females: Relationship to menstrual cycle and body composition. Hepatology 5:701–706. (1983).
Jones AW, Hahn RG and Stalberg H. Distribution of ethanol and water between plasma and whole blood: inter- and intra-individual variations after administration of ethanol by intravenous infusion. Scand. J. Clin. Invest. 50:775–780 (1990).
Iffland R, West A, Bilzer N and Schuff A. Zur Zuverlässigkeit der Blutalkoholbestimmung. Das Verteilungsverhältnis des Wassers zwischen Serum und Vollblut. Rechtsmedizin 9:123–129 (1999).
Winek CL and Carlagna M. Comparison of plasma, serum and whole blood ethanol concentrations. J. Anal. Toxicol. 6:267–268 (1987).
Jones AW and Larsson H. Distribution of diazepam and nordiazepam between plasma and whole-blood and the influence of hematocrit. Ther Drug Monitor 26:380–385 (2004).
Wang MQ, Nicholson ME, Jones CS, Fitzhugh EC and Westerfield CR. Acute alcohol intoxication, body composition, and pharmacokinetics. Pharm. Biochem. Behav. 43:641–643 (1992).
McLean AJ and LeCouleur DG. Aging biology and geriatiric clinical pharmacology. Pharmocol. Rev. 56:163–184 (2004).
Endres HG and Gruner O. Comparison of D2O and ethanol dilutions in total body water measurements in humans. Clin. Investig. 72:830–837 (1994).
Jones AW, Hahn RG and Stalberg HP. Pharmacokinetics of ethanol in plasma and whole blood: Estimation of total body water by the dilution principle. Eur. J. Clin. Pharmacol. 42:445–448 (1992).
Chiou WL. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site; implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics. Clin Pharmacokinet 17:175–199 (1989).
Martin E, Moll M and Schmid P. The pharmacokinetics of alcohol in human breath, venous and arterial blood after oral ingestion. Eur J Clin Pharmacol 26:619–626 (1984).
Jones AW, Norberg Å and Hahn RG. Concentration-time profiles of ethanol in arterial and venous blood and end-expired breath during and after intravenous infusion. J. Forensic Sci. 42:1088–1094 (1997).
Jones AW, Lindberg L and Olsson S-G. Magnitude and time-course of arterial-venous differences in blood-ethanol concentrations in healthy men. Clin Pharmacokinet 43:1157–1166 (2004).
Mather LE. Anatomical-physiological approaches in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 40:707–722 (2001).
Meibohm B, Beierle I and Derendorf H. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 21:329–342 (2002).
Cheymol G. Effects of obesity on pharmacokinetics: Implications for drug therapy. Clin. Pharmacokinet 39:215–31 (2000).
Jones AW. Body mass index and blood-alcohol calculations. J Anal Toxicol 31:177–178 (2007).
Baraona E, Abittan CS, Dohmen K, Moretti M, Pozzato G, Chayes ZW, Schaefer C and Lieber CS. Gender differences in pharmacokinetics of alcohol. Alcohol Clin. Exp. Res. 25:502–507 (2001).
Baraona E, Gentry RT and Lieber CS. Bioavailability of alcohol: Role of gastric metabolism and its interaction with other drugs. Dig Dis 12:351–367 (1994).
Julkunen RJK, Dipadova C and Lieber CS. First pass metabolism of ethanol - A gastrointestinal barrier against the systemic toxicity of ethanol. Life Sci 37:567–573 (1985).
Frezza M, Dipadova C, Pozzato G, Terpin M, Baraona E and Lieber CS. High blood alcohol levels in women - The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med 322:95–99 (1990).
Wagner JG. Lack of first-pass metabolism of ethanol at blood concentrations in the social drinking range. Life Sci 39:407–414 (1986).
Levitt MD. The case against first-pass metabolism of ethanol in the stomach. J Lab Clin Med 123:28–31 (1994).
Levitt MD and Levitt DG. The critical role of the rate of ethanol absorption in the interpretation of studies purporting to demonstrate gastric metabolism of ethanol. J Pharmacol Exp Ther 269:297–304 (1994).
Levitt MD and Levitt DG. Appropriate use and misuse of blood concentration measurements to quantitate first-pass metabolism. J Lab Clin Med 136:275–280 (2000).
Jones AW. Excretion of alcohol in urine and diuresis in healthy men in relation to their age, the dose administered and the time after drinking. Forensic Sci Int 45:217–224 (1990).
Swift R. Direct measurement of alcohol and its metabolites. Addiction 98 Suppl 2:73–80 (2003).
Buono MJ. Sweat ethanol concentrations are highly correlated with co-existing blood values in humans. Exp Physiol 84:401–404 (1999).
Marques PR and McKnight AS. Field and laboratory alcohol detection with 2 types of transdermal devices. Alcohol Clin Exp Res 33:1–9 (2009).
Droenmer P, Schmitt G, Aderjan R and Zimmer H. A kinetic model describing the pharmacokinetics of ethyl glucuronide in humans. Forensic Sci. Int 126:24–29 (2002).
Seidl S, Wurst FM and Alt A. Ethyl glucuronide: a biological marker for recent alcohol consumption. Addic. Biol. 6:205–212 (2001).
Hoiseth G, Bernard JP and Karinen R. et al. A pharmacokinetic study of ethyl glucuronide in blood and urine: Applications to forensic toxicology. Forensic Sci Int 172:119–24 (2007).
Ehring T, Bosron WJ and Li T-K. Alcohol and aldehyde dehydrogenase. Alc. Alcohol. 25:105–116 (1990).
Lieber CS. Cytochrome P-4502E1: Its physiological and pathological role. Physiol Rev 77:517–544 (1997).
Suokas A, Forsander O and Lindros K. Distribution and utilization of alcohol-derived acetate in the rat. J Stud Alcohol 45:381–385 (1984).
Holford NGH. Clinical Pharmacokinetics of ethanol. Clin. Pharmacokinet. 13:273–292 (1987).
Wedel M, Pieters JE, Pikaar NA and Ockhuizen T. Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. Alc Alcohol 26:329–336 (1991).
Norberg Å, Jones A W, Hahn RG and Gabrielsson J. Role of variability in explaining ethanol pharmacokinetics. Clin Pharmacokinet 42:1–31 (2002).
Lundquist F and Wolthers H. The kinetics of alcohol elimination in man. Acta Pharmacol Toxicol 14:265–289 (1958).
Wilkinson PK, Sedman AJ, Sakmar E, Kay DR and Wagner JG. Pharmacokinetics of ethanol after oral administration in the fasting state. J Pharmacokinet Biopharm 5:207–224 (1977).
Wagner JG Wilkinson PK and Games DA. Parameters of Vmax and km for elimination of alcohol in young male subjects following low doses of alcohol. Alc Alcohol 24:555–564 (1989).
Wilkinson PK. Pharmacokinetics of ethanol – A review. Alcohol Clin Exp Res 4:6–21 (1980).
Jones AW. Ultra-rapid rate of ethanol elimination from blood in drunken drivers with extremely high blood-alcohol concentration. Int J Legal Med 122:129–134 (2008).
Simic M and Tasic M. The relationship between alcohol elimination rate and increasing blood alcohol concentration – calculated from two consecutive blood specimens. Forensic Sci Int 172:28–32 (2007).
Li TK, Yin SJ, Crabb DW, O’Connor S and Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res 25:138–144 (2001).
Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 17:7–23 (2003).
Pettersson G. Liver alcohol dehydrogenase. CRC Critical Rev. Biochem. 21:349–389 (1987).
Bonnichsen RK and Wassen A. Crystaline alcohol dehydrogenase from horse liver. Arch Biochem Biophys 18:361–363 (1948).
Bonnichsen RK and Theorell H. An enzymatic method for the micro-determination of ethanol. Scand J Clin lab Invest 3:58–62 (1951).
Peng GS, Yin SJ. Effect of the allelic variants of aldehyde dehydroogenase ALDH2*2 and alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations. Human Genomics 3:121–127 (2009).
Testa B and Kramer SD. The biochemistry of drug metabolism--an introduction: Part 2. Redox reactions and their enzymes. Chem Biodivers 4:257–405 (2007).
Eng MY, Luczak SE and Wall TL. ALDH2, ADH1B, and ADH1C genotypes in Asians: a literature review. Alcohol Res Health 30:22–27 (2007).
Jörnvall H and Höög JO. Nomenclature of alcohol dehydrogenase. Alc. Alcohol 30:153–161 (1995).
Wagner JG. Relationship between first-order and Michaelis-Menten kinetics. J Pharm Sci 78:521–522 (1989).
Pizon AF, Becker CE and Bikin D. The clinical significance of variations in ethanol toxicokinetics. J Med Tox 3:63–72 (2007).
Ostrovsky YM. Endogenous ethanol-its metabolic, behavioral and biomedical significance. Alcohol 3:239–247 (1986).
Logan BK and Jones AW. Endogenous ethanol “autobrewery syndrome” as a drunk driving defense challenge. Med Sci Law 40:206–215 (2000).
Dudley R. Fermenting fruit and the historical ecology of ethanol ingestion: is alcoholism in modern humans an evolutionary hangover? Addiction 97:381–388 (2002).
Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 29:245–254, (2006).
Theorell H and Bonnischsen RK. Studies on liver alcohol dehydrogenase 1 Equilibria and initial reaction velocities. Acta Chem Scand 5:1105–1126 (1951).
Theorell H and Yonetani T. Liver alcohol dehydrogenase-DPN-pyrazole complex – A model of a ternary intermediate in the enzyme reaction. Biochem Z 338:537–553 (1963).
Li TK and Theorell H. Human liver alcohol dehydrogenase inhibition by pyrazole and pyrazole analogs. Acta Chem Scand 23:892–902 (1969).
Blomstrand R, Ostling-Wintzell H, Lof A, McMartin K, Tolf BR and Hedstrom KG. Pyrazoles as inhibitors of alcohol oxidation and as important tools in alcohol research: an approach to therapy against methanol poisoning. Proc Natl Acad Sci 76:3499–3503 (1979).
Galliot M, Astier A, VuBien D and Garnier R et al. Treatment of ethylene glycol poisoning with intravenous 4-methyl pyrazole. N Engl J Med 319:97–100 (1988).
Jacobsen D and McMartin KE. Antidotes for methanol and ethylene glycol poisoning. J Toxicol Clin Tox 35:127–143 (1997).
Brent J. Fomepizole for ethylene glycol and methanol poisoning. N Eng J Med 360:2216–2223 (2009).
Jacobsen D and McMartin KE. Methanol and ethylene glycol poisonings mechanism of toxicity clinical course diagnosis and treatment. Med Toxicol 1:309–334 (1986).
Eder AF, McGrath CM, Dowdy YG, Tomaszewski JE and Rosenberg FM et al. Ethylene Glycol poisoning: toxicokinetics and analytical factors affecting laboratory diagnosis. Clin Chem 44:168–177 (1998).
Sarkola T and Eriksson CJP. Effect of 4-methyl pyrazole on endogenous plasma ethanol and methanol levels in humans. Alcohol Clin Exp Res 25:513–516 (2001).
Karlson-Stibler C and Persson H. Ethylene glycol poisoning: Experiences from an epidemic in Sweden. J Toxicol Clin Tox 30:565–574 (1992).
Mani JC, Pietruszko R and Theorell H. Methanol activity of alcohol dehydrogenase from human liver, horse liver and yeast. Arch Biochem Biophys 140:52–59 (1970).
Röe O. The metabolism and toxicity of methanol. Pharmacol Rev 7:399–412 (1955).
Majchrowicz E and Mendelson JH. Blood methanol concentrations during experimental induced ethanol intoxications in alcoholics. J Pharmacol Exp Ther 179:293–300 (1971).
Jones AW, Skaggerberg S, Yonekura A and Sato A. Metabolic interaction between endogenous methanol and endogenous ethanol studied in human volunteers by analysis of breath. Pharmacol Toxicol 65:48–53 (1990).
Jones AW and Sternebring B. Kinetics of ethanol and methanol in alcoholics during detoxication. Alc Alcohol 27:641–647 (1992).
Haffner H-T, Banger M, Graw M, Besserer K and Brink T. The kinetics of methanol elimination in alcoholics and the influence of ethanol. Forensic Sci Int 89:129–136 (1997).
Kaplan HL, Forney RB, Hughes FW and Jain NC. Chloral hydrate and alcohol metabolism in human subjects. J Forensic Sci 12:295–304 (1967).
Sellers EM, Lang M, Koch-Weser J, LeBlanc E and Kalant H. Interaction of chloral hydrate and ethanol in man. 1. Metabolism. Clin Pharmacol Ther13:37–49 (1972).
Heller PF, Goldberger BA and Caplan YH. Chloral hydrate overdose: trichloroethanol detection by gas chromatography-mass spectrometry. Forensic Sci Int 52:231–234 (1992).
Graham SR, Day RO, Lee R and Fulde GW. Overdose with choral hydrate. A pharmacological and therapeutic review. Med J Aust 149:686–8 (1988).
Inciardi JA. The changing life of Mickey Finn: some notes on chloral hydrate down through the ages. J Pop Cul 11:591–6 (1977).
Baum CR. A century of Mickey Finn – but who was he? J Toxicol Clin Toxicol 38:683 (2000).
Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ and Peacock EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344:87–94 (2002).
Jones C. Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity. J Clin Forensic Med 8:74–76 (2001).
Caldicott DG, Chow FY and Burns BJ et al. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 181:310–313 (2004).
Wojtowicz JM, Yarema MC and Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 10:69–74 (2008).
Lora-Tamayo C, Tena T, Rodriguez A, Sancho JR and Molina E. Intoxication due to 1,4-butanediol. Forensic Sci int 133:256–259 (2003).
Nicholson KL and Balster RL. GHB: a new and novel drug of abuse. Drug Alc Dep 63:1–22 (2001).
Thai D, Dyer JE, Jacob P and Haller CA. Clincial pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Therap 81:178–184 (2007).
Thai D, Dyer JE, Benowitz NL and Haller CA. Gamma-hydroxybutyrate and ethanol effects and interactions in humans. J Clin Pharmacol 26:524–529 (2006).
Lora-Tamayo C, Tena T and Rodriguez A, et al. Intoxication due to 1,4-butanediol. Forensic Sci int 133:256–259 (2003).
Wartburg JP and Bühler R. Biology of disease – alcoholism and aldehydism: new biomedical concepts. Lab Invest 50:5–15 (1984).
Myers RD. Tetrahydroisoquinolines and alcoholism: where are we today? Alcohol Clin Exp Res 20:498–500 (1996).
Crabb DW, Edenberg HJ, Bosron WH and Li T-K. Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. J Clin Invest 83:314–316 (1989).
Eriksson CJP. The role of acetaldehyde in the actions of alcohol (update 2000). Alcohol Clin Exp Res 25:15S-32S (2001).
Mizoi Y, Tatsuno T, Adachi J, Kogame M, Fukunaga T and Fujiwara S et al. Alcohol sensitivity related to polymorphism of alcohol metabolizing enzymes in Japanese. Pharm Biochem Behav 18, Suppl 1:127–133 (1983).
Harada S, Agarwal DP, Normura F and Higuchi S. Metabolic and ethnic determinants of alcohol drinking habits and vulnerability to alcohol-related disorders. Alcohol Clin Exp Res 25:71S-75S (2001).
Bosron WF and Li T-K. Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases and their relationship to alcohol metabolism and alcoholism. Hepatology 6:502–510 (1986).
Goedde HW, Agarwal DP, Harada S. Pharmacogenetics of alcohol sensitivity. Pharmacol Biochem Behav 18 Suppl. 1 161–166 (1983).
Hendershot CS, Collins SE, George WH and Wall TL et al. Associations of ALDH2 and ADH1B genotypes with alcohol-related phenotypes in Asian young adults. Alcohol Clin Exp Res 33:1–9 (2009).
Edenberg HJ. The genetics of alcohol metabolism: role of alcohol dehdrogenase and aldehyde dehydrogenase variants. Alcohol Res Health 30:5–13 (2007)
Yoshida A. Genetic polymorphisms of alcohol metabolizing enzymes related to alcohol sensitivity and alcoholic disease. Alc Alcohol 29:693–696 (1994).
McBride WJ, Li T-K, Deitrich RA, Zimatkin S, Smith BR and Rodd-Henricks ZA. Involvement of acetaldehyde in alcohol addiction. Alcohol Clin Exp Res 26:114–119 (2002).
Quertemont E and Didone V. Role of acetaldehyde in mediating the pharmacological and behavioral effects of alcohol. Alcohol Res Health 29:258–265 (2006).
Lindros KO. Human blood acetaldehyde levels. With improved methods a clearer picture emerges. Alcohol Clin Exp Res 7:70–75 (1983).
Moore S, Montane-Jaime LK, Carr LG and Ehlers CL. Variations in alcohol-metabolizing enzymes in people of East Indian and African descent from Trinidad and Tobago. Alcohol Res Health 30:28–30 (2007).
Wall TL, Carr LG and Ehlers CL. Protective association of genetic variation in alcohol dehydrogenase with alcohol dependence in Native Americans mission Indians. Am J Psychiatry 160:41–46 (2003).
Scott DM and Taylor RE. Health-related effects of genetic variations of alcohol-metabolizing enzymes in African Americans. Alcohol Res Health 30:18–21 (2007).
Ehlers CL. Variations in ADH and ALDH in Southwest California Indians. Alcohol Res Health 30:14–17 (2007).
Hald J and Jacobsen E. A drug sensitizing the organism to ethyl alcohol. Lancet ii:1001–1004 (1948).
Krafh H. From disulfiram to antabuse: the invention of a drug. Bull Hist Chem 33:82–88 (2008).
Peachey JE and Sellers EM. The disulfiram and calcium carbimide acetaldehyde mediated ethanol reaction. Pharmacol Ther 15:89–97 (1981).
Lindberg P, Bergman R and Wickberg B. On the disulfiram-like effect of coprin the pharmacologically active principle of Coprinus atramentarius. Acta Pharmacol Toxicol 42:292–297 (1978).
Jones AW, Neiman J and Hillbom M. Concentration-time profiles of ethanol and acetaldehyde in human volunteers treated with the alcohol-sensitizing drug, calcium carbimide. Br J Clin Pharmacol 25:213–221 (1988).
Lindros KO, Stowell A, Pikkarainen P and Salaspuro M. The disulfiram (antabuse) alcohol reaction in male alcoholics: Its efficient management by 4-methyl pyrazole. Alcohol Clin Exp Res 5:528–530 (1981).
Heath MJ, Pachar JV, Perez-Martinez and Toseland PA. An exceptional case of lethal disulfiram alcohol reaction. Forensic Sci Int 56:45–50 (1992).
Yamamoto H, Tangegashima A, Hosoe H and Fukunaga T. Fatal acute alcohol intoxication in an ALDH2 heterozygote: a case report. Forensic Sci Int 112:201–207 (2000).
Jerntorp P, Ohlin H, Sundkvist G, and Almer LO. Effects of chlorpropamide and alcohol on aldehyde dehydrogenase activity and blood acetaldehyde concentration. Diabetes Res 3:369–372 (1986).
Jerntorp P. The chlorpropamide alcohol flush test in diabetes mellitus: methods for objective evaluation. Scand. J Clin Lab Invest 43:249–254 (1984).
Groop L, Eriksson CJP, Boll-Wåhlin E and Melander A. Chlorpropamide-alcohol flush: significance of body weight, sex, and serum chlorpropamide level. Eur J Clin Pharmacol 26:723–725 (1984).
Chen Z, Zhang J and Stamler JS. Identification of the enzymatic mechanism of nitroglycerine bioactivation. Proc Nat Acad Sci (USA) 99:8306–11 (2002).
Williams CS and Woodcock KR. Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother 34:255–257 (2000).
Cina SJ, Russell RA and Conradi SE. Sudden death due to metronidazole - ethanol interaction. Am J Forensic Med Pathol 17:343–346 (1996).
Visapää J-P, Tillonen JS, Kalhovaara PS and Salaspuro MP. Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother 36:971–974 (2002).
Gonzalez FJ. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res 569:101–10 (2005).
Lieber CS. Microsomal ethanol-oxidizing system (MEOS): The first 30 years (1958–1998) – a review. Alcohol Clin Exp Res 23:991–1007 (1999).
Bertilsson L, Dahl M-L, Dalen P and Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111–122 (2001).
Cho AK, Narimatsu S and Kumagai Y. Metabolism of drugs of abuse by cytochromes P450. Addict Biol 4:283–301 (1999).
Teschke R and Gellert J. Hepatic microsomal ethanol-oxidizing system (MEOS): Metabolic aspects and clinical implications. Alcohol Clin Exp Res 10:20S–32S (1986).
Landrum-Michalets E. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84–112 (1998).
Klotz U and Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur. J. Clin. Pharmacol. 54:7–12 (1998).
Barry M and Feely J. Enzyme induction and inhibition. Pharmacol Ther 48:71–94 (1990).
Lin JH and Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35:361–390 (1998).
Pelkonen, O and Sotaniemi E. Drug metabolism in alcoholics. Pharmacol Ther 16:261–268 (1982).
Nakajima T. Cytochrome P450 isoforms and the metabolism of volatile hydrocarbons of low relative molecular mass. J. Occup. Health 99:83–101 (1997).
Murray M and Reidy GF. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev. 42:85–101 (1990).
Keiding S, Christensen NJ and Damgaard SE et al. Ethanol metabolism in heavy drinkers after massive and moderate alcohol intake. Biochem. Pharmacol. 32:3097–3102 (1983)
Oneta CM, Lieber AS, Li J, Rüttimann S, Schmid B, Lattmann J, Rosman AS and Seitz HK. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J. Hepatol. 36:47–52 (2002).
Park BK, Pirmohamed M and Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol Ther 58:385–424 (1995).
Park BK, Kitteringham NR, Pirmohamed M and Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br. J. Clin. Pharmacol. 41:477–91 (1996).
Ramdhan DH, Kamijima M, Yamada N, Ito Y, Yanagiba Y and Nakamura D, et al. Molecular mechanism of trichloroethylene-induced hepatotoxicity mediated by CYP2E1. Toxicol Appl Pharmacol 231:300–7 (2008).
Park DV, Ioannides C and Lewis DFV. The role of the cytochrome P450 in the detoxication and activation of drugs and other chemicals. Can. J. Physiol. Pharmacol. 69:537–549 (1991).
Salmela KS, Kessova IG, Tsyrlov IB and Lieber CS. Respective roles of human cytochrome P4502E1 1A2 and 3A4 in the hepatic microsomal oxidizing system. Alcohol. Clin. Exp. Res. 22:2125–2132 (1998).
Tanaka E, Terada M and Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Therap 25:165–175 (2000).
Makin AJ and Williams R. Acetaminophen-induced hepatotoxicity: Predisposing factors and treatments. Adv Intern Med. 42:3433–483 (1997).
Slattery JT, Nelson SD and Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 60:241–246 (1996).
Prescott LF. Paracetamol, alcohol and the liver. Br. J. Clin. Pharmacol. 49:291–301 (2000).
Lee SS, Buters JT, Pineau T, Fernandez-Salguero P and Gonzalez FJ. Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063–12067 (1996).
Schmidt LE and Dalhoff K. Concomitant overdosing of other drugs in patients with paracetamol poisoning. Br J Clin Pharmacol 53:535–541 (2002).
Riordan SM and Williams R. Alcohol exposure and paracetamol-induced hepatotoxicity. Addict Biol 7:191–206 (2002).
Thomas SHL. Paracetamol (acetaminophen) poisoning. Pharmacol Ther 60:91–120 (1993).
Vale JA and Proundfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 346:547–552 (1995).
Zimmerman HJ and Maddrey WC. Acetaminophen (paracetamol) hepatoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 22:767–773 (1995).
Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E and Benjamin SB. Acetaminophen hepatotoxicity in alcoholics. Ann Intern Med 104:399–404 (1986).
Rumack BH. Acetaminophen hepatotoxicity: The first 35 years. Clin Toxicol 40:3–20 (2002).
Makin AJ, Wendon J and Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987–1993). Gastroenterology 109:1907–1916 (1995).
Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: A critical review. J Toxicol Clin Toxicol 36:277–285 (1998).
Whitcomb DC and Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 272:1845–1850 (1994).
Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE and Watkins PB. Ethanol and production of the hepatoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther 67:591–599 (2000).
Janes J and Routledge PA. Recent developments in the management of paracetamol (acetaminophen) poisoning. Drug Safety 7:170–177 (1992).
Jones AL. Recent advances in the management of poisoning. Ther Drug Monit 24:150–155 (2002).
Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 359:285–92 (2008).
Pond SM and Tozer TN. First-pass elimination; Basic concepts and clinical consequences. Clin Pharmacokinet 9:1–25 (1984).
Conney AH. Drug metabolism and therapeutics. N Engl J Med 280:653–660 (1969).
Lin JH, Chiba M and Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135–157 (1999).
DiPadova C, Roine R, Frezza M, Gentry RT, Baraona E and Lieber CS. Effects of ranitidine on blood alcohol levels after ethanol ingestion. Comparison with other H2-receptor antagonists. JAMA 267:83–86 (1992).
Hempel JD and Pietruszko R. Human stomach alcohol dehydrogenase: isoenzyme composition and catalytic properties. Alcohol Clin Exp Res 3:95–98 (1979).
Baraona E, Yokoyama A, Ishii H, Hernandez-Munoz R and Takagi T et al. lack of alcohol dehydrogenase isoenzyme activity in the stomach of Japanese subjects. Life Sci 49:1929–1934 (1991).
Caballeria J, Frezza M, Hernandez–Munoz R, Dipadova C, Korsten MA, Baraona E and Lieber CS. Gastric origin of the first-pass metabolism of ethanol in humans: Effect of gastrectomy. Gastroenterology 97:1205–1209 (1989).
Gentry RT, Baraona E and Lieber CS. Gastric first pass metabolism of alcohol. J Lab Clin Med 123:21–26 (1994).
Lieber CS. Hepatic, metabolic and nutritional disorders of alcoholism: from pathogenesis to therapy. Crit Rev Clin Lab Sci 37:551–584 (2000).
Julkunen RJK, Tannenbaum L, Baraona E and Lieber CS. First-pass metabolism of ethanol: An important determinant of blood levels after alcohol consumption. Alcohol 2:437–441 (1985).
Roine R, Gentry RT, Hernandez-Munoz R, Baraona E and Lieber CS. Aspirin increases blood alcohol concentrations in humans after ingestion of ethanol. JAMA 264:2406-2408 (1990).
DiPadova C, Worner TM, Julkunen RJK and Lieber CS. Effects of fasting and chronic alcohol consumption on the first-pass metabolism of ethanol. Gastroenterology 92:1169–1173 (1987).
Lim RT, Gentry RT, Ito D, Yokoyarna H, Baraona E and Lieber CS. First-pass metabolism of ethanol is predominantly gastric. Alcohol Clin Exp Res 17:1337–1344 (1993).
Lieber CS. Gastritis in the alcoholic, relationship to gastric alcohol metabolism and Helicobacter pylori. Addict Biol 3:423–434 (1998).
Gupta AM, Baraona E and Lieber CS. Significant increase of blood alcohol by cimetidine after repetitive drinking of small alcohol doses. Alcohol Clin Exp Res 19:1093–1087 (1995).
Levitt MD. Do histamine-2 receptor antagonists influence the metabolism of ethanol. Ann Intern Med 118:564–565 (1993).
Arora S, Baraona E and Lieber CS. Alcohol levels are increased in social drinkers receiving ranitidine. Am J Gastroenterol 95:208–213 (2000).
Oneta CM, Simanowski UA, Martinez M and Allali-Hassani A et al. First pass metabolism of ethanol is strikingly influenced by the speed of gastric emptying. Gut 43:612–619 (1998).
Horowitz M, Maddox A and Bochner M, et al. Relationship between gastric emptying of solid and caloric liquid meals and alcohol absorption. Am J Physiol 257:G291–G298 (1989).
Mattila MJ and Venho VMK. Drug absorption from abnormal gastrointestinal tract. Prog Pharmacol 2:63–86 (1979).
Madsen JL. Effects of gender, age, and body mass index on gastrointestinal transit times. Dig Dis Sci 37:1548–1553 (1992).
Ammon E, Schäfer C, Hoffmann U and Klotz U. Disposition and first pass metabolism of ethanol in humans: Is it gastric or hepatic and does it depend on gender? Clin Pharmacol Ther 59:503–513 (1996).
Petring OU and Flachs H. Intersubject and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption. Br J Clin Pharmacol 29:703–708 (1990).
Lartigue S, Bizais Y, Desvarannes SB, Murat A, Pouliquen B and Galmiche JP. Inter- and intrasubject variability of solid and liquid gastric emptying parameters - a scintigraphic study in healthy subjects and diabetic patients. Dig Dis Sci 39:109–115 (1994).
Elashoff JD, Reedy TJ and Meyer JH. Analysis of gastric emptying data. Gastroenterology 83:1306–1312 (1982).
Goo RH, Moore JG, Greenberg E and Alazraki NP. Circadian variations in gastric emptying of meals in humans. Gastroenterology 93:515–518 (1987).
Hunt JN and Stubbs DF. The volume and energy content of meals as determinants of gastric emptying. J Physiol 245:209–225 (1975).
Rinetti M, Ugolotti G, Calbiani B, Colombi-Zinelli L, Cisternino M and Papa N. Anti-inflammatory drugs and gastric emptying. A comparison between acetylsalicylic acid and carprofen. Arzneimittelforschung 32:1561–1563 (1982).
Pfeiffer A, Högl B and Kaess H. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin Investig 70:487–491 (1992).
Mascord D, Smith J, Starmer G and Whitfield J. Effect of increasing the alcohol metabolism rate on plasma acetate concentration. Alc Alcohol 27:25–28 (1992).
O’Conner S, Morzorati S, Christian J and Li TK. Clamping breath alcohol concentration reduces experimental variance: Application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res 22:202–210 (1998).
Ramchandani VA, O’Connor S, Meumark Y, Zimmermann US, Morzorati SL and de Witt, H. The alcohol clamp: applications, challenges, and new directions – an RSA 2004 symposium summary. Alcohol Clin Exp Res 30:155–164 (2006).
Svensson CK, Edwards DJ, Mauriello PM, Barde SH and Foster AC et al. Effect of food on hepatic blood flow. Implications in the “food effect” phenomenon. Clin Pharmacol Ther 34:316–323 (1983).
Palmer RH, Frank WO, Nambi P, Wetherington JD and Fox MJ. Effects of various concomitant medications on gastric alcohol dehydrogenase and the first-pass metabolism of ethanol. Am J Gastroenterol. 86:1749–1755 (1991).
Melander O, Liden A and Melander A. Pharmacokinetic interactions of alcohol and acetylsalicylic acid. Eur J Clin Pharmacol 48:151–153 (1995).
Gentry RT, Baraona E, Amir I, Roine R, Chayes ZW, Sharma R and Lieber CS. Mechanism of the aspirin-induced rise in blood alcohol levels. Life Sci 65:2505–2512 (1999).
Locher KB, Mallach HJ, and Moosmayer A. Pharmacokinetishe Wechselwirkungen zwischen Alkohol und Acetylsalicylsäure. Blutalkohol 28:273–278 (1991).
Kechagias S, Jönsson KÅ, Norlander B, Carlsson B and Jones AW. Low-dose aspirin decreases blood alcohol concentrations by delaying gastric emptying. Eur J Clin Pharmacol 53:241–246 (1997).
Heading RC, Nimmo J, Prescott LF and Tothill P. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 47:415–421 (1973).
Barron SE, Perry JR and Ferslew KE. The effect of ibuprofen on ethanol concentration and elimination rate. J Forensic Sci 37:432–435 (1992).
Minocha A, Barth JT, Herold DA, Gideon DA and Spyker DA. Modulation of ethanol-induced central nervous system depression by ibuprofen. Clin Pharmacol Ther 39:123–127 (1986).
Greiff JMC and Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 27:447–461 (1994).
Madsen JL. Effects of cisapride on gastrointestinal transit in healthy humans. Dig Dis Sci 35:1500–1504 (1990).
McCallum RW, Prakash C, Campoli-Richards DM and Goa KL. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 36:652–681 (1988)
Dziekan G, Contesse J, Werth B, Schwarzer G and Reinhart WH. Cisapride increases peak plasma and saliva ethanol levels under fasting conditions. J. Intern Med 242:479–482 (1997).
Kechagias S, Jönsson KÅ and Jones AW. Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride. Br J Clin Pharmacol 48:728–732 (1999).
Deponti F, Giaroni C, Cosentino M, Lecchini S and Frigo G. Calcium-channel blockers and gastrointestinal motility - basic and clinical aspects. Pharmacol Ther 60:121–148 (1993).
Bauer LA, Schumock G, Horn J and Opheim K. Verapamil inhibits ethanol elimination and prolongs the perception of intoxication. Clin Pharmacol Ther 52:6–10 (1992)
Perez-Reyes M, White WR and Hicks RE. Interaction between ethanol and calcium channel blockers in humans. Alcohol Clin Exp Res 16:769–775 (1992).
Edelbroek MAL, Horowitz M, Wishart JM and Akkermans LMA. Effects of erythromycin on gastric emptying, alcohol absorption and small intestinal transit in normal subjects. J Nucl Med 34:582–588 (1993).
Peeters T, Matthijs G, Depoortere I, Cachet T, Hoogmartens J and Vantrappen G. Erythromycin is a motilin receptor agonist. Am J Physiol 257:G470–G474 (1989).
Urbain JL, Vantrappen G, Janssens J, Van Cutsem E, Peeters T and De Roo M. Intravenous erythromycin dramatically accelerates gastric emptying in gastroparesis diabeticorum and normals and abolishes the emptying discrimination between solids and liquids. J Nucl Med 31:1490–1493 (1990).
Smith SR and Kendall MJ. Ranitidine and cimetidine: A comparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 15: 44–56 (1988).
Hernandez-Munoz R, Caballeria J, Baraona E, Uppal R, Greenstein R and Lieber CS. Human gastric alcohol dehydrogenase - Its inhibition by H2-receptor antagonists, and its effect on the bioavailability of ethanol. Alcohol Clin Exp Res 14:946–950 (1990).
Amir I, Anwar N, Baraona E and Lieber CS. Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Life Sci 58:511–518 (1996).
Bye A, Lacey LF, Gupta S and Powell JR. Effect of ranitidine hydrochloride (150 mg twice daily) on the pharmacokinetics of increasing doses of ethanol (0.15, 0.3, 0.6 g kg-1). Br J Clin Pharmacol 41:129–133 (1996).
Toon S, Khan AZ, Holt BI, Mullins FG, Langley SJ and Rowland MM. Absence of effect of ranitidine on blood alcohol concentrations when taken morning, midday, or evening with or without food. Clin Pharmacol Ther 55:385–391 (1994).
Raufman JP, Notarfrancesco V, Raffaniello RD and Straus EW. Histamine-2 receptor antagonists do not alter serum ethanol levels in fed, non-alcoholic men. Ann Intern Med 118:488–494 (1993).
Tanaka E and Nakamura, K. Effects of H-2 receptor antagonists on ethanol metabolism in Japanese volunteers. Br J Clin Pharmacol 26: 96–99 (1988).
Somogyi, A and Muirhead, M. Pharmacokinetic interactions of cimetidine. Clin. Pharmacokinet. 12:321–366 (1987).
Caballeria J, Baraona E, Rodamilans M and Lieber CS. Effects of cimetidine on gastric alcohol dehydrogenase activity and blood ethanol levels. Gastroenterology 96:388–392 (1989).
Dauncey H, Chesher GB and Palmer RH. Cimetidine and ranitidine: Lack of effect on the pharmacokinetics of an acute ethanol dose. J Clin Gastroenterol 17:189–194 (1993).
Fraser AG, Hudson M, Sawyerr AM, Smith M, Rosalki SB and Pounder RE. Ranitidine, cimetidine, famotidine have no effect on post-prandial absorption of ethanol 0.8 g/kg taken after an evening meal. Aliment Pharmacol Ther 6:693–700 (1992).
Fraser AG, Prewett EJ, Hudson M, Sawyerr AM, Rosalki SB and Pounder RE. The effect of ranitidine, cimetidine or famotidine on low-dose post-prandial alcohol absorption. Aliment Pharmacol Ther 5:263–272 (1991).
Clemmesen JO, Ott P and Sestoft l. The effect of cimetidine on ethanol concentrations in fasting women and men after two different doses of alcohol. Scand J Gasterenterol 32:217–220 (1997).
Casini A, Pizzigallo AM, Mari F, Bertol E and Surrenti C. Prolonged bedtime treatment with H2-receptor antagonists (ranitidine and famotidine) dose not affect blood alcohol levels after ethanol ingestion in male patients with duodenal ulcer. Am J Gastroenterol 89:745–749 (1994).
Sharma R, Gentry RT, Lim RT and Lieber CS. First-pass metabolism of ethanol: Absence of diurnal variation and its inhibition by cimetidine after evening meal. Dig Dis Sci 40:2091–2097 (1995).
Seitz HK, Bösche J, Czygan P, Veith S, Simon B and Kommerell B. Increased blood ethanol levels following cimetidine but not ranitidine. Lancet ii, 700 (1983).
Seitz HK, Veith S, Czygan P, Bösche J, Simon B, Gugler R and Kommerell B. In-vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology 4:1231–1233 (1984).
Feely J and Wood AJJ. Effects of cimetidine on the elimination and actions of ethanol. JAMA 247: 2819–2821 (1982).
Webster LK, Jones BD and Smallwood RA. Influence of cimetidine and ranitidine on ethanol pharmacokinetics. Austr NZ J Med 15: 359–360 (1985).
Dobrilla G., de Pretis G and Piazzi L., et al. Is ethanol metabolism affected by oral administration of cimetidine and ranitidine at therapeutic doses?. Hepatogastroenterology 31:35–37 (1984).
Jönsson K-Å, Jones AW, Boström KL and Andersson T. Lack of effect of omeprazole, cimetidine and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers. Eur J Clin Pharmacol 42:209–212 (1992).
Fraser AG. Is there an interaction between H2-antagonists and alcohol? Drug Metabol Drug Interact 14:123–145 (1998).
Crabbe DW. First-pass metabolism of ethanol; Gastric or hepatic: Mountain or molehill. Gasterenterology 25:1292–1294 (1997).
Zakhari S and Li T-K. Determinants of alcohol use and abuse. Impact of quantity and frequency patterns on liver disease. Hepatology 46:2032–2039 (2007).
Lieber CS. The metabolism of alcohol. Sci Am 234:25–34 (1976).
Lieber CS. Alcohol and the liver – metabolism of alcohol and its role in hepatic and extrahepatic diseases. Mount Sin J med 67:84–94 (2000).
Hawkins RD and Kalant H. The metabolism of ethanol and its metabolic effects. Pharmacol Rev 24:67–157 (1972).
Gable RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 99:686–696 (2004).
Nutt D, King LA, Saulsbury W and Blakemore C. Development of a rational scale to assess the harm of drugs of potential abuse. Lancet 369:1047–53 (2007).
Antkowiak B. How do general anaesthetic work? Naturwissenschaften 88:201–213 (2001).
Urban BW and Bleckween M. Concepts and correlations relevant to general anaesthesia. Br J Anesth 89:3–16 (2002).
Campagna JA, Miller KW and Forman SA. Mechnaism of action of inhaled anesthetics. N Eng J Med 348:2110–2124 (2003).
Little HJ. Mechanisms that may underlie the behavioural effects of ethanol. Prog Neurbiol 36:171–194 (1991).
Lüddens H, Pritchett DB, Köhler M and Killisch I et al. Cerebellar GABAA receptor selective for a behavioural alcohol antagonist. Nature 346:648–651 (1990).
Gilpin NW and Koob GF. Neurobiology of alcohol dependence. Alc Res Health 31:185–195 (2008)
Lovinger DM. Alcohols and neurotransmitter gated ion channels: past, present and future. Namyn-Schmiedeberg’s Arch Pharmacol 356:267–282 (1997).
Claoo P, Bhave SV and Hoffman PL. How adaptation of the brain to alcohol leads to dependence. A pharmacological perspective. Alc Res Health 31:310–339 147 (2008).
Bormann J. The ABC of GABA receptors. Trends Pharmacol Sci 21:16–19 (2000).
Pritchett DB, Sontheimer H, Shivers BD and Ymer S et al. Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology. Nature 338:582–585 (1989).
Meheta AK and Ticku MK. An update on GABAA receptors. Brain Res Bull 29:196–217 (1999).
Rudolph U, Crestani F and Möhler H. GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188–194 (2001).
Nagy J. Alcohol related changes in regulation of NMDA receptor functions. Curr Neuropharmacol 6:39–54 (2008).
Vengeliene V, Bilbao A, Molander A and Spanagel R. Neuropharmacology of alcohol addiction. Br J Pharmacol 154:299–315 (2008).
Tupala E and Tühonen J. Dopamine and alcoholism. Neurobiological basis of ethanol abuse. Prog Neuro-psychopharmacol Biol Psych 28:1221–1247 (2004).
Hobbs WR, Rall TW and Verdoorn TA. Hypnotics and sedatives; ethanol. Chapter 17 in Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th edition, McGraw-Hill, New York, 361–396 (1996).
Byatt C and Volans G. ABC of poisoning: sedative and hypnotic drugs. Br Med J 289:1214–1217 (1984).
Gary NE and Tresznewsky O. Barbiturates and a potpourri of other sedative, hypnotics, and tranquilizers. Heart & Lung 12:122–127 (1983).
Johnson HRM. At what blood levels does alcohol kill? Med Sci Law 25:127–130 (1985).
Odesanmi WO. The fatal blood alcohol level in acute poisoning. Med Sci Law 23:25–30 (1983).
Kalant H. Research on tolerance: What can we learn from history. Alcohol Clin Exp Res 22:67–76 (1998).
Ekman G, Frankenhaeuser M, Goldberg L and Bjerver K et al. Effects of alcohol intake on subjective and objective variables over a five-hour period. Psychopharmacologia 4:28–38 (1963).
Mellanby E. Alcohol: Its absorption into and disappearance from the blood under different conditions. Special report Series No. 31, London, National Safety Council, (1919).
Cruz MT, Bajo M, Schweitizer P and Roberto M. Shared mechanisms of alcohol and drug tolerance. Alc Res Health 31:137–147 (2008).
Pietrzykowski AZ and Treistman SN. The metabolic basis of tolerance. Alc Res Health 31:298–309 (2008).
Alha A. Blood alcohol and clinical inebriation in Finnish men – A medico-legal study. Ann Acad Sci Fenn Series A. V. Medica-Anthropologica 26:1–92 (1951).
Jones AW and Holmgren P. Comparison of blood-ethanol concentration in deaths attributed to acute alcohol poisoning and chronic alcoholism. J Forensic Sci. 48:874–9 (2003).
Koski A, Ojanperä I and Vuori E. Alcohol and benzodiazepines in fatal poisonings. Alcohol Clin Exp Res 26:956–959 (2002).
Becker HC. Alcohol dependence, withdrawal, and relapse. Alc Res Health 31:348–361 (2008).
Jones AW. The drunkest drinking driver in Sweden; blood alcohol concentration 0.545% w/v. J Stud Alcohol 60:400–406 (1999).
Urso T, Gavaler JS and Van Thiel DH. Blood ethanol levels in sober alcohol users seen in an emergency room. Life Sci. 28:1053–1056 (1985).
Jones AW. Alcohol; post-mortem. Encyclopedia of Forensic Sciences, Academic Press Inc., London 2000, pp 112–126.
Correy JEL. Possible sources of ethanol ante- and post-mortem. Its relationship to the biochemistry and microbiology of decomposition. J Appl Bacteriol 44:1–56 (1978).
Kalant H and Le AD. Effects of ethanol on thermoregulation. Pharmacol Ther 23:313–364 (1984).
Ward ME and Cowley AR. Hypothermia: A natural cause of death. Am. J. Forensic Med. Pathol 20:383–386 (1999).
Gallaher MM, Fleming DW, Berger LR and Sewell CM. Pedestrian and hypothermia deaths among native Americans in New Mexico. JAMA 267:1345–2348 (1992).
Kortelainen ML. Drugs and alcohol in hyporthermia and hypethermia related deaths. A retrospective study. J Forensic Sci 32:1704–12 (1987).
Larach MG. Accidential hypothermia. Lancet 345:493–498 (1995).
Lundevall J, Olaisen B, Olving JH and Clausen OPE et al. Blodkonsentrasjoner ved akutte forgiftningsdodsfall. Tidsskr. Nor. Laegeforen 103:679–685 (1983).
Padosch SA, Schmidt PH, Kröner LU and Madea B. Death due to positional asphyxia under severe alcoholisation: pathophysiologic and forensic considerations. Forensic Sci Int 149:67–73 (2005).
De Donno A, De Fazio A, Greco MG, Introna F and Maglietta RAG. Death in head-down position in a heavily intoxicated obese man. Leg Med 10:204–309 (2008).
Glatter K and Karch SB. Positional asphyxia: inadequate oxygen or inadequate theory? Forensic Sci int 141:201–202 (2004).
Byard RW, Wick R and Gilbert JD. Conditions and circumstances predisposing to death from positional asphyxia in adults. J Forensic Leg Med 15:415–419 (2008).
Thomsen JL, Theilade P, Felby S and Nielsen E. Alcoholic ketoacidosis as a cause of death in forensic cases. Forensic Sci Int 75:163–171 (1995).
Thomsen JL. Various mechanisms of death and their possible association with alcoholism. Forensic Sci Int 79:199–204 (1996).
Pounder DJ, Stevenson RJ and Taylor KK. Alcoholic ketoacidosis at autopsy. J Forensic Sci 43:812–816 (1998).
Brinkmann B, Fechner G, Karger B and DuChesne A. Ketoacidosis and lactic acidosis – frequent causes of death in chronic alcoholics? Int J Legal Med 111:115–119 (1998).
Felby S, Nielsen E and Thomsen JL. The post-mortem distribution of ketone bodies between blood, vitreous humor, spinal fluid and urine. Forensic Sci Med Pathol 4:100–107 (2008).
Lahti RA and Vuori E. Fatal alcohol poisoning: medico-legal practices and mortality statistics. Forensic Sci Int 126:203–209 (2002).
Höjer J, Baehrendtz S and Gustafsson L. Benzodiazepine poisoning: experience of 702 admissions to an intensive care unit during a 14-year period. J Intern Med 226:117–122 (1989).
Buckley NA, Dawson AH, Whyte IM and O’Connell DL. Relative toxicity of benzodiazepines in overdose. Br Med J 310:219–221 (1995).
Serfaty M and Masterton G. Fatal poisonings attributed to benzodiazepines in Britain during the 1980s. Br J Psychiatry 163:383–93 (1993).
Drummer OH and Ranson DL. Sudden death and benzodiazepines. Am J Forensic Med Pathol 7:336–342 (1996).
Tanaka E. Toxicological interactions between alcohol and benzodiazepines. J Toxicol Clin Toxicol 40:69–75 (2002).
Caplan YH, Ottinger WE and Crooke CR. Therapeutic and toxic drug concentrations in post mortem. A six year study in the state of Maryland. J Anal Toxicol 7:225–230 (1983).
Jonasson B, Jonasson U and Saldeen T. The manner of death among fatalities where dextropropoxyphene caused or contributed to death. Forensic Sci Int 96:181–187 (1998).
Jonasson U, Jonasson B, Holmgren P and Saldeen T. The prevalence of dextropropoxyphene in autopsy blood samples. Forensic Sci Int 96:135–142 (1998).
Sturner WQ and Garriott JC. Deaths involving propoxyphene: A study of 41 cases over a two-year period. JAMA 223:1125–1130 (1973).
Buckley BM and Vale JA. Dextropropoxyphene poisoning: problems with interpretation of analytical data. Hum Toxiciol 3:95–101 (1984).
Young RJ. Dextropropoxyphene overdosage: pharmacological considerations and clinical management. Drugs 26:70–79 (1983).
Finkle BS, Caplan YH, Garriott JC, Montforte JR, Shaw RF and Sonsalla PK. Propoxyphene in postmortem toxicology 1976–1978. J Forensic Sci 26:739–57 (1981).
Finkle BS. Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds. Hum. Toxicol Supp. 115S–134S (1984).
Tallman JF, Paul SM, Skolnick P and Gallager DW. Receptors for the age of anxiety: Pharmacology of the benzodiazepines. Science 207:274–281 1980.
Carmen Del Rio M, Prada C and Alvarez FJ. Do Spanish patients drink alcohol while undergoing treatment with benzodiazepines? Alcohol 26:31–34 (2002).
Drummer OK, Syrjanen ML and Cordner SM. Deaths involving the benzodiazepine flunitrazepam. Am. J Forensic Med Pathol 14:238–243 (1993).
Druid H, Holmgreen P and Ahlner J. Flunitrazepam: an evaluation of use, abuse and toxicity. Forensic Sci Int 122: 136–141 (2001).
Fisher E, and Von Mering J. Ueber eine neue Klasse von Schlafmittlen. Ther. d. Gegenw 44:97–101 (1903).
Adams E. The barbiturates. Sci Am 198:60–64 (1958).
Gillespie RD. On the alleged dangers of the barbiturates. Lancet (Feb 17): 337–345 (1934).
Koniaris LG, Zimmers TA, Lubarsky DA and Sheldon JP. Inadequate anaesthesia in lethal injection for execution. Lancet 365:1412–4 (2005).
Stead AH and Moffatt AC. Quantification of the interaction between barbiturates and alcohol at different concentrations. Hum Toxicol 2:5–14 (1983).
Stead AH, Allan AR, Ardrey RE and Bal TS, et al. Drug misuse – the barbiturate problem. J Forensic Sci Soc 21:41–53 (1981).
Teige D and Fleischer E. Blodkonsentrasjoner ved akutte forgiftningsdodsfall. Tidsskr nor Laegeforen 103:679–685 (1983).
George CFP. Pyrazolopyrimidines. Lancet 358:1623–1626 (2001).
Baenninger A, Costa e Silva JA, Hindmarch I, Moeller HJ and Rickels K. Good chemistry – The life and legacy of valium inventor Leo Sternbach. McGraw-Hill, New York, (2004).
Woods JH and Wingler G. Abuse liability of flunitrazepam. J Clin Psychopharmacol 17:1S–57S (1997).
Laurijssens BE and Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 30:52–76 (1996).
Steentoft A and Worm K. Cases of fatal triazolam poisoning. J Forensic Sci Soc 33:45–48 (1993).
Sunter JP, Bal TS and Cowan WK. Three cases of fatal triazolam poisoning. Br Med J 297:719 (1998).
Steentoft A, Teige B, Ceder G and Vuori E et al. Fatal poisoning in drug addicts in the Nordic countries. Forensic Sci Int 123:63–69 (2001).
Finkle BS, McCloskey KL and Goodman LS. Diazepam and drug-associated deaths. JAMA 242:429–434 (1979).
Homgren P and Jones AW. Coexistence and concentrations of ethanol and diazepam in postmortem blood samples: Risk for enhanced toxicity? J Forensic Sci 48:1416–1421 (2003).
Mandelli M, Tognono G and Gerattini S. Clinical pharmacokinetics of diazepam. Clin. Pharmacokinet. 3:72–91 (1978).
Greenblatt DJ, Harmatz JS, Friedman H, Locnisker A and Shader RI. A large sample study of diazepam pharmacokinetics. Ther Drug Monit 11:652–657 (1989).
Greenblatt DJ, Laughren TP, Allen, MD, Harmatz JS and Shader RI. Plasma diazepam and desmethyldiazepam concentrations during long term diazepam therapy. Br J Clin Pharmacol 1:35–40 (1981).
Joynt BP. Triazolam blood concentrations in forensic cases in Canada. J Anal Toxicol 17:171–177 (1993).
Edwards JG. Medicolegal aspects of benzodiazepine dependence: Duties and responsibilities of doctors. Med J Aust 156:733–737 (1992).
Laisi U, Linnoila M, Seppälä T, Himberg I-J and Mattila MJ. Pharmacokinetic and pharmacodynamic interactions of diazepam with different alcoholic beverages. Eur J Clin Pharmacol 16:263–270 (1979).
Costa E and Guidotti A. Benzodiazepines on trial: a research strategy for their rehabilitation. Trends Pharmacol Sci 17:192–200 (1996).
Garretty DJ, Wolff K, Hay AWM and Raistrick D. Benzodiazepine misuse by drug addicts. Ann Clin Biochem 34:68–73 (1997).
Woods JH, Katz JL and Winger G. Abuse liability of benzodiazepines. Pharmacol Rev 39:251–419 (1987).
Woods JH, Katz JL and Winger G. Benzodiazepines: use, abuse and consequences. Pharmacol Rev 44:151–347 (1992).
Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 356:1505–1511 (2000).
Möhler H, Fritschy JM and Rudolph U. A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300:2–9 (2002).
Liebreich O. Das Chloralhydrat. Ein neues hypnoticum und anaestheticum und dessen anwendung in der Medicin. Otto Müller’s Verlag, Berlin, (1869).
Jonasson B and Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int 126:1–6 (2002).
Worm K, Dragsholt C, Simonsen K and Kringsholm B. Citalopram concentrations in samples from autopsies and living persons. Int J Legal Med 111:188–190 (1998).
Bailey DN and Shaw RF. Interpretation of blood and tissue concentrations in fatal self-poisoning overdoses involving amitriptyline: An update 1978–1979. J Anal Toxicol 4:232–236 (1980).
Tournier M, Grolleau A, Cougnard A, Verdoux H and Molimard M. The prognostic impact of psychotropic drugs in intentional drug overdose. Pharmacopsychiatry 42:51–56 (2009).
Pennings EJM, Leccese AP and de Wolff FA. Effects of concurrent use of alcohol and cocaine. Addiction 97:773–779 (2002).
Farre M, de la Torre R, Gonzalez ML, Teran MT, Roset PN, Menoyo E and Cami J. Cocaine and alcohol interactions in humans: Neuroendocrine effects and cocaethylene metabolism. J Pharmacol Exp Ther 283:164–176 (1997).
Hearn WL, Rose S, Wagner J, Ciarleglio A and Mash DC. Cocaethylene is more potent than cocaine in mediating lethality. Pharmacol Biochem Behav 39:531–533 (1991).
McCance EF, Price LH, Kosten TR and Jatlow P. Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther 274:215–223 (1995).
Andrews P. Cocaethylene toxicity. J Addict Diseases 16:75–84 (1997).
Bailey DN. Serial plasma concentrations of cocoethylene, cocaine, and ethanol in trauma victims. J Anal Toxicol 17:79–83 (1993).
Bailey DN. Comprehensive review of cocaethylene and cocaine concentrations in patients. Am J Clin Pathol 106:701–704 (1996).
Jatlow P. Cocaethylene. Pharmacologic activity and clinical significance. Ther Drug Monit 15:533–536 (1993).
Jatlow P, McChance EF, Bradberry CW, Elsworth JD, Taylor JR and Roth RH. Alcohol plus cocaine: The whole is more than the sum of its parts. Ther Drug Monit 18:460–464 (1996).
Schuckit MA. Alcohol-use disorder. Lancet 373:492–499 (2009).
Dawson DA. Methodological issues in measuring alcohol use. Alcohol Res Health 27:18–29 (2003).
Ewing, J. A. Screening for alcoholism using CAGE. Cut down, Annoyed, Guilty, Eye opener. JAMA 280:1904–1905 (1998).
Hannuksela ML, Liisanantti MK, Nissinen AE and Savolainen MJ. Biochemical markers of alcoholism. Clin Chem Lab Med 45:953–961 (2007).
Jones AW. Biomarkers of acute and chronic alcohol consumption. Chapter 4 in Medicolegal Aspects of Alcohol, 5th edition, J.C. Garriott. Ed. Lawyers & Judges Publishing Co., Inc., Tucson, 2008, pp 157–203.
Saitz R. Unhealthy alcohol use. N Eng J Med 352:596–607 (2005).
Garbutt JC, West SL, Carey TS, Lohr KN and Crews FT. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA 281:1318–1325 (1999).
Kreek MJ, LaForge KS and Butelman E. Pharmacotherapy of addictions. Nature Rev Drug Disc 1:710–726 (2002).
Johnson BA. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34–56 (2008).
Leggio L, Kenna GA and Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Prog Neuropsychopharmacol Biol Psychiatry 32:1106–1117 (2008).
Johnson BA, Swift RM, Addolorato G, Ciraulo DA and Myrick H. Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res 29:248–254 (2005).
Johnsen J, Stowell A, Stensrud T, Ripel A and Morland J. A double-blind placebo controlled study of healthy volunteers given a subcutaneous disulfiram implantation. Pharmacol Toxicol 66:227–230 (1990).
Swift RM. Medications and alcohol craving. Alc Res Health 23:207–213 (1999).
Attard A, Ranjith G and Taylor D. Delirium and its treatment. CNS Dtugs 22:631–644 (2008).
Hughes JR. Alcohol withdrawal seizures. Epilepsy Behav 15:92–97 (2009).
Carter LP, Pardi D, Gorsline J and Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 104:1–10 (2009).
Wedin GP, Hornfeldt CS and Ylitalo LM. The clinical development of gamma-hydroxy butyrate (GHB). Curr Drug Saf 1:99–106 (2006).
Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, Gessa Gl and Palatini P. Pharmacokinetics of gamma-hydroxybutyrate in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 34:231–235 (1992).
Carai MAM, Colombo G, Reali R and Serra S et al. Central effects of 1,4 butanediol are mediated by GABAB receptors via its conversion into γ-hydroxybutyric acid. Eur J Pharmacol 441:157–163 (2002).
Caputo F, Vignoli T, Maremmani I, Bernardi M and Zoli G. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health. 6:1917–1929 (2009).
Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T and Lorenzini F, et al. Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol 17:781–9 (2007).
Swift RM. Effect of naltrexone on human alcohol consumption. J Clin Psychiatry 56 (supp. 7) 24–29 (1995).
Krystal JH, Cramer JA, Krol WF, Kirk GF and Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 345:1734–39 (2001).
Swift RM. Opioid antagonists and alcoholism treatment. CNS Spectr 5:49–57 (2000).
Anton RF. Naltrexone for the management of alcohol dependence. N Engl J Med 359:715–21 (2008).
Ray LA, Hutchison KE, MacKillop J, Miranda R Jr., Audette A, Swift R and Monti PM. Effects of naltrexone during the descending limb of the blood alcohol curve. Am J Addict 17:257–264 (2008).
Baros AM, Latham PK and Anton RF. Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res 32:771–776 (2008).
Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R, Jr and McGeary JE, et al. Moderators of naltrexone’s effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32:58–66 (2008).
Mann K, Kiefer F, Spanagel R and Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32:1105–1110 (2008).
Boothby LA and Doering PL. Acamprosate for the treatment of alcohol dependence. Clin Ther 27:695–714 (2005).
Wilde MI and Wagstaff AJ. Acamprosate – A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53:1038–1053 (1997).
Swift RM, Davidson D, Whelihan W and Kuznetsov O. Ondansetron alters human alcohol intoxication. Biol Psychiatry 40:514–21 (1996).
Swift RM. Topiramate for the treatment of alcohol dependence: initiating abstinence. Lancet 361:1666–1667 (2003).
Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L and Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res 32:1251–1259 (2008).
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L and Beyers K, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168:1188–1199 (2008).
Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L and Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651 (2007).
Miranda R, Jr., MacKillop J, Monti PM, Rohsenow DJ, Tidey J and Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489–497 (2008).
Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L and Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915–1922 (2007).
Agabio R, Marras P, Addolorato G, Carpiniello B and Gessa GL. Baclofen suppresses alcohol intake and craving for alcohol in a schizophrenic alcohol-dependent patient: a case report. J Clin Psychopharmacol 27:319–320 (2007).
Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, Davidson D and Swift R. The effect of olanzapine on craving and alcohol consumption. Neuropsycho-pharmacology 31:1310–1317 (2006).
Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D and Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl) 155:27–34 (2001).
Garbutt JC. The state of pharmacotherapy for the treatment of dependence. J Subst Abuse Treat 36:S15-S23 (2009).
Linnoila M and Mattila MJ. How to antagonize ethanol-induced inebriation. Pharmacol Ther 15:99–109 (1981).
Schneble H. Ernüchterungsmittel – nüchtern betrachtet. Blutalkohol 25:18–65 (1988).
Carni J and Farre M. Drug addiction. N Eng J Med 349:975–986 (2003).
Jones AW. Forensic science aspects of ethanol metabolism. Forensic Sci Prog 31:229–238 (1991).
Wiese JG, Shlipak MG and Browner WS. The alcohol hangover. Ann Intern Med 132:897–902 (2000).
Prat G, Adan A and Sanchez-Turet M. Alcohol hangover. A critical review of explanatory factors. Hum Psychopharmacol Clin Exp 24:259–267 (2009).
Stephens R, Ling J, Heffernan TM, Heather N and Jones K. A review of the literature on the cognitive effects of alcohol hangover. Alcohol Alcohol 43:163–170 (2008).
Ylikahri RH, Leino T, Huttunen MO, Poso AR, Eriksson CJ and Nikkila EA. Effects of fructose and glucose on ethanol-induced metabolic changes and on the intensity of alcohol intoxication and hangover. Eur J Clin Invest 6:93–102 (1976).
Rowland J, Rohsenow DJ, Allensworth-David D and Greece J et al. The incidence and severity of hangover the morning after moderate alcohol consumption. Addiction 103:758–765 (2008).
Pittler MH, Verster JC and Ernst E. Interventions for preventing or treating alcohol hangover: systematic review of randomized controlled trials. BMJ 331:1515–1518 (2005).
Goldberg L, Jones AW and Neri A. Effect of a sugar mixture on blood ethanol profiles and on ethanol metabolism in man. Blutalkohol 16:431–438 (1988).
Soterakis J and Iber FL. Increased rate of alcohol removal from blood with oral fructose and sucrose. Am J Clin Nut 28:254–257 (1975).
Clark ER, Hughes IE and Letley E. The effect of oral administration of various sugars on blood ethanol concentration in man. J Pharm Pharmacol 25:309–323 (1973).
Mascord D, Smith J, Starmer GA and Whitfield JB. The effect of fructose on alcohol metabolism and on the lactate/pyruvate ratio in man. Alc Alcohol 26:53–59 (1991).
Crow KE, Newland KM and Batt RD. The fructose effect. NZ Med J 93:232–234 (1981).
Bode C. The metabolism of alcohol: Physiological and pathological aspects. J Roy Coll Phys 12:122–135 (1978).
Cohen RD. Effect of fructose on blood alcohol level. Lancet ii:1086 (1972).
Lister R and Nutt DJ. Is RO 15–4513 a specific alcohol antagonist?. Trends Neur Sci 10:223–225 (1987).
Allan AN and Harris RA. A new alcohol antagonist: Phaclofen. Life Sci 45:1771–1779 (1989).
Polacsek P. Interaction of alcohol and other drugs an annotated bibliography. Addiction Research Foundation, Toronto pp 1–535 (1970).
Li J, Mills T and Erato R. Intravenous saline has no effect on blood ethanol clearance. J Emerg Med 17:1–5 (1999).
Hyvärinen J, M. Laakso, H. Sippel and Roine R. et al. Alcohol detoxification accelerated by oxygenated drinking water. Life Sci 22:553–560 (1978).
Ylikahri R and Leino T. Metabolic interactions of xylitol and ethanol in healthy males. Metabolism 28:25–29 (1979).
Alkana RL, Parker ES, Cohen HB, Birch H and Nobel EP. Interaction of sted-eze, nikethamide, pipradrol, or ammonium chloride with ethanol in human males. Alcohol Clin Exp Res 4:84–92 (1980).
Kelly M, Myrsten AL and Goldberg L. Intravenous vitamins in acute alcoholic intoxication: effects on physiological and psychological functions. Br J Addict 66:19–30 (1971).
Chen MF, Boyce Worth H and Hsu JM. Effect of ascorbic acid on alcohol clearance. J Am Coll Nutrit 9:185–189 (1990).
Susick RL and Zannoni VG. Effect of ascorbic acid on the consequences of acute alcohol consumption in humans. Clin Pharmacol Ther 41:502–509 (1987).
Linnoila M, Mattila MJ, Karhunen P, Nuotto E and Seppäla T. Failure of TRH and ORG 2766 hexapeptide to counteract alcoholic inebriation in man. Eur J Clin Pharmacol 21:27–32 (1981).
Kraemer R, Mallach HJ, Raff G and Schulz H. Influence of mobiletten on the effect of alcohol drinking in man. Int J Clin Pharmacol 15:301–309 (1977).
Mallach HJ, Raff G and Kraemer R. On the influence of mobiletten on the effect of alcohol in the human. Int J Clin Pharmacol 15:576–580 (1977).
Miller LG. Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158:2200–2211 (1998).
Azcona O, Barbanol MJ, Torrent J and Jane F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol 40:393–400 (1993).
Liguori A and Robinson JH. Caffeine antagonism of alcohol-induced driving impairment. Drug Alc Depend 63:123–129 (2001)
Shoaf SE and Linnoila M. Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications. Psychopharm Bull 27:577–594 (1991).
Mendelson J, Jones RT, Upton R and Jacob P. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 57:559–568 (1995).
Mattila MJ, Kuitunen T and Pletan Y. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. Eur J Clin Pharmacol 43:179–184 (1992).
Lader M, Melhuish A, Frcka G, Fredricson Overo K and Christensen V. The effects of citalopram in single and repeated doses and with alcohol on physiological and psychological measures in healthy subjects. Eur J Clin Pharmacol 31:183–190 (1986).
Van Harten J, Stevens LA, Raghoebar M and Holland RL et al. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clin Pharmacol Ther 52:427–436 (1992).
Naranjo CA, Sullivan JT, Kadlec KE, Woodley-Remus DV, Kennedy G and Sellers EM. Differential effects of viqualine on alcohol intake and other consummatory behaviors. Clin Pharmacol Ther 46:301–309 (1989).
Anton R, Paladino JA, Morton A and Thomas RW. Effect of acute alcohol consumption on lithium kinetics. Clin Pharmacol Ther 38:52–55 (1985).
Dole VP, Fishman J, Goldfrank L, Khanna J and McGivern RF. Arousal of ethanol-intoxicated comatose patients with naloxone. Alcohol Clin Exp Res 6:275–279 (1982).
Bodd E., Beylich M, Christophersen A and Morland J. Oral administration of codeine in the presence of ethanol: A pharmacokinetic study in man. Pharmacol Toxicol 61:297–300 (1987).
Donnelly B, Balkon J, Lasher C and DePaul Lynch V et al. Evaluation of the methadone-alcohol interaction. 1. Alterations of plasma concentration kinetics. J Anal Toxicol 7:246–248 (1983).
Griffin JP, D’Arcy PF and Speirs CJ. A manual of adverse drug interactions. 4th edition, Wright, London 1988.
Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T. Fatal adverse drug events. The paradox of drug treatment. J Intern Med 250:327–341 (2001).
Ebbesen J, Buajordet I,, Erikssen J, Brors O, Hilberg T et al. Drug-related deaths in a department of internal medicine. Arch Intern Med 161:2317–2323 (2001).
Bjornaas MA, Jacobsen D, Haldorsen T and Ekeberg O. Mortality and cases of death after hospital treated self-poisoning in Oslo, A 20-year follow up. Clin Toxicol 47:116–123 (2009).
Hovda KE, Bjornaas MA, Skog K, Opdahl A. et al. Acute poisonings treated in hospitals in Oslo: A one-year prospective study (I): Pattern of poisoning. Clin Toxicol 46:35–41 (2008).
Heyerdahl F, Bjornaas MA, Hovda KE, Skog K, et al. Acute poisonings treated in hospitals in Oslo: A one-year prospective study (II): Clinical outcome. Clin Toxicol 46:42–49 (2008).
Jönsson A, Holmgren P and Ahlner J. (2004) Fatal intoxications in a Swedish forensic autopsy material during 1992–2002. Forensic Sci Int 143:53–9 (2004).
Wester K, Jönsson AK, Spigset O, Druid H, and Hägg S. Incidence of fatal adverse drug reactions a population based study Br J Clin Pharmacol 65:573–579 (2008).
Lazarou J, Poimeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA 279:1200–1205 (1998).
Room R, Babor T, Rehm J. Alcohol and public health. Lancet 365:519–530 (2005).
Avorn J. Dangerous deception - hiding the evidence of adverse drug effects. N Engl J Med 355:2169–2171 (2006).
Phillips DP, Jarvinen JR and Phillips RR. A spike in fatal medication errors at the beginning of each month. Pharmacotherapy 25:1–9 (2005).
Phillips DP, Christenfeld N and Ryan NM. An increase in the number of deaths in the United States in the first week of the month. N Eng J Med 341:93–98 (1999).
Ulrich RG. Idiosyncratic toxicity: A convergence of risk factors. Annu Rev Med 58:17–34 (2007).
Bugelski PJ. Genetic aspects of immue-mediated adverse drug effects. Nat Rev Drug Disc 4:59–69 (2005).
Knowles SR, Uetrecht J and Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndrome. Lancet 356:1587–1591 (2000).
Logan BK and Distefano S. Ethanol content of various foods and soft drinks and their potential for interference with a breath-alcohol test. J Anal Toxicol 22:181–183 (1998).
Baum CR, Shannon MW and Woolf A. Breath and blood ethanol following use of a cough-cold preparation. J Tox Clin Tox 35:643–644 (1997).
Mallon L, Broman J-E and Hetta J. Is usage of hypnotics associated with mortality. Sleep Med 10:279–286 (2009).
Schmidt G. Detection and estimation of barbituric acid derivatives. Methods of Forensic Science edited by F Lundquist, vol 1, Interscience Publishers pp 373–496, (1962).
Druid H and Holmgren P. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J Forensic Sci 42:79–87 (1997).
Jones AW, Holmgren A and Kugelberg F. Concentrations of scheduled prescription drugs in blood of impaired drivers. Considerations for interpreting the results. Ther Drug Monit 29:248–260, (2007).
Katz DA, Murray B, Bhathema A, Schelijo L. Defining drug disposition determinants: a pharmacogenetic pharmacokinetic strategy. Nat rev Drud disc 7:293–305 (2008).
Pelkonen O, Kapitulnik J, Gundert-Remy U, Boobis AR, Stockis A. Local kinetics and dynamics of xenobiotics. Clin Rev Toxicol 38:697–720 (2008).
Nestler EJ. Genes and addiction. Nature Med 26:277–281 (2000).
Mayfield RD, Harris RA, Schuckit MA. Genetic factors influencing alcohol dependence. Br J Pharmacol 154:275–287 (2008).
Koob GF, Lloyd GK, Mason NJ. Development of pharmacotherapies for drug addiction: a Rosetta Stone approach. Nat rev Drug Disc 8:500–515 (2009).
Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13 (2005).
Ingelman-Sundberg M and Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos Trans R Soc Lond B Biol Sci 360:1563–1570 (2005).
Ingelman-Sundberg M, Sim SC, Gomez A and Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526 (2007).
Nebert DW and Russell DW Clinical importance of the cytochromes P450. Lancet 360:1155–1162 (2002).
Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. The AAPS journal 8:E101-E111 (2006).
Kirchheiner J and Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 1770:489–494 (2007).
Ingelman-Sundberg M. Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120: 259–268 (2001).
Pirmohamed M and Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 22:298–305 (2001).
Nebert DW. Drug-metabolizing enzymes, polymorphisms and interindividual response to environmental toxicants. Clin Chem Lab Med 38:857–861 (2000).
Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 359:1667–1671 (2000).
Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherpy. J Intern Med 250:186–200 (2001).
Evans WE, and McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 348:538–549 (2003).
Shurin SB, and Nabel EG. Pharmacogenomics--ready for prime time? N Engl J Med 358:1061–1063 (2008).
Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med 359:856–858 (2008).
Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Therap 84:417–423 (2008).
Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 45:957–964 (2006).
Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 336:1667–1671 (2000).
Li T-K. Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking. J Studies Alc 61:5–12 (2000).
Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 49:369–379 (1997).
Li T-K, Yin SJ, Crabb DW, O’Connor S and Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res 25:136–144 (2001).
Vesell ES, Page JG and Passananti GT. Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther 12:192–201 (1971).
Kim BH, Yi S, Kim J, Lim KS et al. Influence of alcohol on the hemodynamic effects and pharmacokientic properties of mirodenafil: A single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea. Clin Therap 31:1234–1243 (2009).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Jones, A.W. (2012). Pharmacokinetic and Pharmacodynamic Interactions Between Alcohol and Other Drugs. In: Mozayani, A., Raymon, L. (eds) Handbook of Drug Interactions. Humana Press. https://doi.org/10.1007/978-1-61779-222-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-61779-222-9_13
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-221-2
Online ISBN: 978-1-61779-222-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)